579 Chinese medicines named in the latest list (with list)

Medicine Network October 12, more than 500 chinese medicine varieties list announced recently, with the support of the Chinese Pharmaceutical Society, the Chinese medicine major varieties alliance jointly with Wanfang data and other units, issued the "Chinese medicine large varieties of scientific and technological competitiveness report."
It is understood that the report uses scientific and technological factors to measure the scientific and technological competitiveness of Chinese medicine, thus reflecting the "clinical value, scientific value" of the product, and through sales to reflect the "market value" of the product - a comprehensive consideration of the above three dimensions, from the listed 59595 Chinese medicine products, selected in the 2019 evaluation of scientific and technological competitiveness of 579 varieties of Chinese medicine.
In addition, the report also clarifies the concept of large varieties of Chinese medicine, and the traditional sales as the basis for judging large varieties is different, large varieties of Chinese medicine refers to a significant or accurate clinical efficacy, to meet clinical needs, high scientific and technological content, Chinese medicine features significant, a large market share of varieties.
Cypress blue combing found that the list of varieties are basically clinically commonly used, high-profile large varieties, involving a number of well-known pharmaceutical companies: including the blood lipid Kang capsules of Beida Weixin bio, TongrenTang's Uji white phoenix pills, plate blue root particles, Angong cattle yellow pills and six-flavored yellow pills (concentrated pills), Yiling Pharmaceuticals Ginseng heart capsules, Guangzhou Baiyunshan small Chaihu particles, Qing Kailing particles (capsules), Guizhou Sanli Pharmaceutical's throat sword spray (children's type), China Resources 39's ginseng injection, raw pulse injection, Jichuan Pharmaceuticals' Pudi blue anti-inflammatory oral solution and small children's anti-inflammatory particles ... Data show that China's Chinese medicine approval number of nearly 60,000, and this time only 579 large varieties on the list, basically are clinically commonly used in various therapeutic fields of advantage products, which to a certain extent represents a higher level of the Chinese medicine industry.
With the normalization of medical insurance fee control, drug supervision, key monitoring and health insurance payment policies need scientific decision-making and evidence support, and the publication of the chinese medicine large varieties of scientific and technological competitiveness report, supporting expert evaluation, but also to provide important data support for scientific decision-making.
Indeed, because of "no guidance recommendation", "inadequate clinical evidence", "suitable for a variety of diseases" and other reasons, so that many large varieties of Chinese medicine in the hospital, clinical use, drug proportion assessment has been subject to many restrictions.
in order to solve this problem, a number of Chinese medicine enterprises have re-tweed the course, through a reasonable and effective way to prove their clinical efficacy and safety.
to a certain extent, pharmaceutical companies can support the clinical value and scientific value of their products through this report, which reflects the clinical value of drugs and scientific value, thus promoting market access, academic promotion and hospital sales.
Traditional Chinese medicine, innovation problem is a difficult problem at present, the overall level of science and technology of traditional Chinese medicine is low, with China's drug review system gradually to international standards, its theory and development law of Chinese medicine gradually drift away, that is, the review standard of "Westernization" and the listing and innovation of chinese medicine is incompatible, chinese medicine innovation is still blocked and long.
drug review report issued by the State Drug Administration identified this dilemma from a data perspective: data show that between 2012 and 2017, 37, 27, 11, 61, 2 and 2 Chinese medicines were approved for listing, while 588, 389 chemical drugs (including biological drugs) were approved for listing in the same period. 486, 290, 204, 492, the number of six-year approval of listed chemical drugs (biological drugs) is 2449, while the same period approved for listing of Chinese medicine only 140, accounting for 5.4% of the total number of approvals, of which only 57 new Chinese medicine, not only the number of very low, but also a continuous decline trend.
Because the raw materials come from natural plants and animals, the composition is complex, the principle of drug action is not clear, Chinese medicine in the research and development process is difficult to achieve standardization like chemical drugs, which also caused the lack of innovation in the research and development of Chinese medicine.
And this time, "The scientific and technological competitiveness of large varieties of Chinese medicine" focuses on the evaluation of scientific and technological competitiveness carried out by third parties: according to the evaluation model of scientific and technological competitiveness of large varieties of Traditional Chinese medicine, the value of scientific and technological competitiveness of chinese medicine varieties in the past 10 years has been calculated - scientific and technological factors.
scientific and technological factors are the concentrated reflection of the "clinical value and scientific value" of Chinese medicine products.
that is to say, the listed products are basically clinical advantages, high-tech content, distinctive Chinese medicine, which to a certain extent guide the industry to the direction of scientific and technological innovation.
Market space is large, strong Hengqiang overall, the chinese medicine industry market size shows a steady growth trend, in 2014-2018, China's Chinese medicine industry market size with a compound annual growth rate of 6.9% continued to grow, by 2018, the chinese medicine industry market size reached 149.754 billion yuan, the market size is expected to reach 223.676 billion yuan in 2023.
fact, since 2015, the state has vigorously developed Chinese medicine, Chinese medicine good policy began to "blowout".
with a long history, the industry has more large-scale leading enterprises.
data show that as of December 2018, the size of the Chinese medicine industry in more than 20 million enterprises have more than 1500, more than 40 pharmaceutical companies completed the listing, such as Tongrentang, Yunnan White Medicine, 39 Pharmaceuticals and so on.
, there are still a number of small and medium-sized enterprises in the industry, such products exist homogenization phenomenon, profitability needs to be strengthened.
From the current situation, only the development prospects of better leading Chinese medicine enterprises, because of abundant capital, good cash flow, can invest in research and development, maintain product innovation, promote the sustainable development of the Chinese medicine industry - this shows that the strong Hengqiang is still the future proposition of the Chinese medicine industry.
.